Le Lézard
Classified in: Health, Science and technology, Business
Subjects: VEN, PSF

AU10TIX Secures New Investment to Fuel Further Growth and Innovation in the Fast-Growing Identity Verification and Document Verification Market


NICOSIA, Cyprus, Dec. 4, 2019 /PRNewswire/ -- AU10TIX, a global cloud-based, machine learning, ID verification and authentication platform, recently announced a $20 million investment from Venture Growth-equity Fund Oak HC/FT into ABC Technologies B.V., Parent of AU10TIX Limited. The investment further enables AU10TIX to distinguish itself in the growing identity verification and document verification market.

AU10TIX - Secure Customer Onboarding (PRNewsfoto/AU10TIX)

There is a clear and present need for third party physical ID verifications across a variety of industry verticals. Physical ID verification is considered mission critical for many customers to help prevent fraud, increase trust and safety and enforce KYC ("know your customer") compliance.

"AU10TIX's end-to-end solution is transforming the way Fortune 500 companies across industries verify and authenticate their users," said Matt Streisfeld, partner at Oak HC/FT. "We are thrilled to partner with AU10TIX as their vision leads the industry forward and the company continues its significant momentum."

AU10TIX is well positioned to enable these key business processes with its portfolio of services, which includes: forensic level ID authentication, identity verification, screening, and advanced biometrics.  Over the last decade AU10TIX has become the preferred solution for customer onboarding and KYC automation across a diverse set of industry sectors: such as banking, payments, transportation, travel, and gaming.  AU10TIX is listed among OWIs top Identity Companies in their recent industry landscaping.

"AU10TIX has established itself as a leader in global customer onboarding and forensic level identity authentication, and is distinguishing itself through advanced machine learning, talent acquisition, and global expansion through new investments and an unmatched customer base," said Ron Atzmon, CEO, AU10TIX.

About AU10TIX

AU10TIX Limited specializes in the authentication and digitization of identifying documents including Passports, identity cards, driving licenses and other complementary identifying documents. The company specializes in providing software-based solutions used for scanning, identifying, content retrieval, authentication and validation of identifying documents. AU10TIX is a pioneer of all-channel (front-end and online) ID authentication and processing solutions. AU10TIX is a subsidiary of ICTS International N.V. For more information, visit www.au10tix.com

About Oak

Founded in 2014, Oak HC/FT (http://oakhcft.com) is the premier venture growth-equity fund investing in Healthcare Information & Services ("HC") and Financial Services Technology ("FT"). With $1.9 billion in assets under management, Oak HC/FT is focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to its extensive network of industry leaders. Oak HC/FT is headquartered in Greenwich, CT with offices in Boston and San Francisco. Follow Oak HC/FT on TwitterLinkedIn and Medium.

Contact:

AU10TIX 
[email protected]
Heather Dahill

 

SOURCE AU10TIX


These press releases may also interest you

at 23:38
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

at 23:33
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

at 22:54
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

at 22:03
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

at 20:35
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: